117 related articles for article (PubMed ID: 26013041)
1. Cationic, amphiphilic dextran nanomicellar clusters as an excipient for dry powder inhaler formulation.
Vadakkan MV; Binil Raj SS; Kartha CC; Vinod Kumar GS
Acta Biomater; 2015 Sep; 23():172-188. PubMed ID: 26013041
[TBL] [Abstract][Full Text] [Related]
2. Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin.
Pai RV; Jain RR; Bannalikar AS; Menon MD
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):179-95. PubMed ID: 26406162
[TBL] [Abstract][Full Text] [Related]
3. Development of porous particles using dextran as an excipient for enhanced deep lung delivery of rifampicin.
Kadota K; Yanagawa Y; Tachikawa T; Deki Y; Uchiyama H; Shirakawa Y; Tozuka Y
Int J Pharm; 2019 Jan; 555():280-290. PubMed ID: 30471373
[TBL] [Abstract][Full Text] [Related]
4. Dry-Powder Inhaler Formulation of Rifampicin: An Improved Targeted Delivery System for Alveolar Tuberculosis.
Rawal T; Kremer L; Halloum I; Butani S
J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):388-398. PubMed ID: 28510480
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of highly branched cyclic dextrin in inhalable particles of combined antibiotics for the pulmonary delivery of anti-tuberculosis drugs.
Kadota K; Senda A; Tagishi H; Ayorinde JO; Tozuka Y
Int J Pharm; 2017 Jan; 517(1-2):8-18. PubMed ID: 27913241
[TBL] [Abstract][Full Text] [Related]
6. A new respirable form of rifampicin.
Son YJ; McConville JT
Eur J Pharm Biopharm; 2011 Aug; 78(3):366-76. PubMed ID: 21324356
[TBL] [Abstract][Full Text] [Related]
7. Co-spray drying of hygroscopic kanamycin with the hydrophobic drug rifampicin to improve the aerosolization of kanamycin powder for treating respiratory infections.
Momin MAM; Tucker IG; Doyle CS; Denman JA; Sinha S; Das SC
Int J Pharm; 2018 Apr; 541(1-2):26-36. PubMed ID: 29458207
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections.
Vandenheuvel D; Singh A; Vandersteegen K; Klumpp J; Lavigne R; Van den Mooter G
Eur J Pharm Biopharm; 2013 Aug; 84(3):578-82. PubMed ID: 23353012
[TBL] [Abstract][Full Text] [Related]
9. Dry powder cationic lipopolymeric nanomicelle inhalation for targeted delivery of antitubercular drug to alveolar macrophage.
Vadakkan MV; Annapoorna K; Sivakumar KC; Mundayoor S; Kumar GS
Int J Nanomedicine; 2013; 8():2871-85. PubMed ID: 23990716
[TBL] [Abstract][Full Text] [Related]
10. Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections.
Matinkhoo S; Lynch KH; Dennis JJ; Finlay WH; Vehring R
J Pharm Sci; 2011 Dec; 100(12):5197-205. PubMed ID: 22020816
[TBL] [Abstract][Full Text] [Related]
11. Optimization of a dry powder inhaler of ciprofloxacin-loaded polymeric nanomicelles by spray drying process.
Farhangi M; Mahboubi A; Kobarfard F; Vatanara A; Mortazavi SA
Pharm Dev Technol; 2019 Jun; 24(5):584-592. PubMed ID: 30431373
[TBL] [Abstract][Full Text] [Related]
12. [Design of Spray-dried Porous Particles for Sugar-based Dry Powder Inhaler Formulation].
Kadota K
Yakugaku Zasshi; 2018; 138(9):1163-1167. PubMed ID: 30175760
[TBL] [Abstract][Full Text] [Related]
13. Potential of aerosolized rifampicin lipospheres for modulation of pulmonary pharmacokinetics and bio-distribution.
Singh C; Koduri LV; Dhawale V; Bhatt TD; Kumar R; Grover V; Tikoo K; Suresh S
Int J Pharm; 2015 Nov; 495(2):627-32. PubMed ID: 26392246
[TBL] [Abstract][Full Text] [Related]
14. Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis.
Rawal T; Parmar R; Tyagi RK; Butani S
Colloids Surf B Biointerfaces; 2017 Jun; 154():321-330. PubMed ID: 28363192
[TBL] [Abstract][Full Text] [Related]
15. Particle engineering of materials for oral inhalation by dry powder inhalers. II-Sodium cromoglicate.
Nolan LM; Li J; Tajber L; Corrigan OI; Healy AM
Int J Pharm; 2011 Feb; 405(1-2):36-46. PubMed ID: 21129460
[TBL] [Abstract][Full Text] [Related]
16. A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics.
Chan JG; Chan HK; Prestidge CA; Denman JA; Young PM; Traini D
Eur J Pharm Biopharm; 2013 Feb; 83(2):285-92. PubMed ID: 22982733
[TBL] [Abstract][Full Text] [Related]
17. Physical and immunogenic stability of spray freeze-dried influenza vaccine powder for pulmonary delivery: comparison of inulin, dextran, or a mixture of dextran and trehalose as protectants.
Murugappan S; Patil HP; Kanojia G; ter Veer W; Meijerhof T; Frijlink HW; Huckriede A; Hinrichs WL
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):716-25. PubMed ID: 23933147
[TBL] [Abstract][Full Text] [Related]
18. Particle engineering of materials for oral inhalation by dry powder inhalers. I-Particles of sugar excipients (trehalose and raffinose) for protein delivery.
Ogáin ON; Li J; Tajber L; Corrigan OI; Healy AM
Int J Pharm; 2011 Feb; 405(1-2):23-35. PubMed ID: 21129458
[TBL] [Abstract][Full Text] [Related]
19. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.
Park CW; Li X; Vogt FG; Hayes D; Zwischenberger JB; Park ES; Mansour HM
Int J Pharm; 2013 Oct; 455(1-2):374-92. PubMed ID: 23820131
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of rifampicin after repeated intra-tracheal administration of amorphous and crystalline powder formulations to Sprague Dawley rats.
Khadka P; Sinha S; Tucker IG; Dummer J; Hill PC; Katare R; Das SC
Eur J Pharm Biopharm; 2021 May; 162():1-11. PubMed ID: 33639255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]